Literature DB >> 31873873

Association between serum cell adhesion molecules with hs-CRP, uric acid and VEGF genetic polymorphisms in subjects with metabolic syndrome.

Hamideh Ghazizadeh1,2, Majid Rezaei2, Amir Avan1,2, Mohammad Fazilati3, Alireza Pasdar2,4, Shima Tavallaie2, Elham Kazemi5, Seyed Mohammad Reza Seyedi6,7, Gordon A Ferns8, Mohsen Azimi-Nezhad9,10,11, Majid Ghayour-Mobarhan12.   

Abstract

Metabolic syndrome (MetS) is associated with a pro-inflammatory state and endothelial dysfunction that places subjects with MetS at a higher risk of atherosclerosis. Inflammatory biomarkers are raised in patients at risk of developing cardiovascular diseases. In the current study, we aimed to examine the possible association between MetS and serum soluble adhesion molecules, hs-CRP, uric acid, and the genetic variations related to vascular endothelial growth factor (VEGF) gene. In this cross-sectional study, participants were enrolled from the Mashhad stroke and heart atherosclerotic disorders (MASHAD) study. The International Diabetes Federation criteria were used to define the MetS. Cell adhesion molecules (CAM) and serum hs-CRP were measured by ELISA and PEG-enhanced immunoturbidimetry method, respectively. We used a logistic regression analysis to determine independent associations of CAMs with the VEGF polymorphisms and MetS. Two hundred and 59 participants with and without MetS were enrolled. Participants with MetS and DM had a significantly higher serum E-selectin level (p < 0.05). Participants with a high serum E-selectin level had higher levels of hs-CRP, FBG, TG, uric acid, BMI and lower levels of serum HDL-C (p < 0.05). Interestingly, individuals with MetS with a genetic variant of the VEGF gene (rs6921438) had higher level of serum ICAM-1 (p = 0.04). There were significant associations between serum E-selectin concentrations and the presence of MetS, and its risk factors. Moreover, we demonstrated that MetS subjects with the rs6921438 genetic variant had a higher serum level of ICAM-1 (p < 0.05).

Entities:  

Keywords:  Cell adhesion molecules; Metabolic syndrome; Polymorphism; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2019        PMID: 31873873     DOI: 10.1007/s11033-019-05081-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  5 in total

1.  Association between dietary patterns and body composition in normal-weight subjects with metabolic syndrome.

Authors:  Mohammad Rashidmayvan; Payam Sharifan; Susan Darroudi; Sara Saffar Soflaei; Rahil Salaribaghoonabad; Nilufar Safari; Maryam Yousefi; Mohadese Honari; Hamideh Ghazizadeh; Gordon Ferns; Habibollah Esmaily; Majid Ghayour-Mobarhan
Journal:  J Diabetes Metab Disord       Date:  2022-05-28

2.  Genetic Scores of eNOS, ACE and VEGFA Genes Are Predictive of Endothelial Dysfunction Associated Osteoporosis in Postmenopausal Women.

Authors:  Puneetpal Singh; Monica Singh; Rubanpal Khinda; Srishti Valecha; Nitin Kumar; Surinderpal Singh; Pawan K Juneja; Taranpal Kaur; Sarabjit Mastana
Journal:  Int J Environ Res Public Health       Date:  2021-01-22       Impact factor: 3.390

3.  Diagnostic Value of Color Doppler Flow Imaging Combined with Serum CRP, PCT, and IL-6 Levels for Neonatal Pneumonia.

Authors:  Wenru Chen; Xiaoqing Yu
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-10       Impact factor: 2.650

4.  Comparative study evaluating antihistamine versus leukotriene receptor antagonist as adjuvant therapy for rheumatoid arthritis.

Authors:  Tarek Mohamed Mostafa; Sahar Kamal Hegazy; Salwa El-Morsy Abd El-Ghany; Fedaa Abd El-Monem Kotkata
Journal:  Eur J Clin Pharmacol       Date:  2021-07-04       Impact factor: 2.953

5.  Effect of C reactive protein on the sodium-calcium exchanger 1 in cardiomyocytes.

Authors:  Yong Xie; Qian Li; Hai-Feng Zhang; Tu-Cheng Huang; Ying Yang; Yong-Qing Lin; Jing-Ting Mai; Zhu-Zhi Wen; Wo-Liang Yuan; Jing-Feng Wang; Yang-Xin Chen
Journal:  Exp Ther Med       Date:  2021-05-28       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.